Novo Says May Take Years to Comply With FDA Request
Feb. 11 (Bloomberg) -- Novo Nordisk A/S Chief Executive Officer Lars Rebien Soerensen discusses the U.S. Food and Drug Administration's decision not to approve the insulin maker's Tresiba diabetes treatment, saying more data on heart safety is needed. He talks from Copenhagen with Francine Lacqua on Bloomberg Television's "On the Move." (Source: Bloomberg)
Most Recent Videos
Is the Bond Market Calling the Fed's Rate Bluff?
41:17 - Bond traders are calling the Fed's bluff. For weeks now, everyone from Janet Yellen to Fed newcomer Patrick Harker has been trying to jawbone investors into believing an interest-rate increase in March is on the table. That the meeting is “live.” Yet try as they might, the bond market seems unconvinced there’s much behind the tough talk. Bloomberg's Brian Chappatta has more on "Bloomberg Markets." (Source: Bloomberg)